• Explore /
  • Poster
  • / IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

Abstract Video & Slides Poster

Authors

null

Michel Ducreux

Gustave Roussy Cancer Center, Villejuif, France

Michel Ducreux , Andrew X. Zhu , Ann-Lii Cheng , Peter R. Galle , Masafumi Ikeda , Alan Nicholas , Wendy Verret , Lindong Li , Vincent E. Gaillard , Riccardo Lencioni , Richard S. Finn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03434379

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4071)

DOI

10.1200/JCO.2021.39.15_suppl.4071

Abstract #

4071

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

First Author: Valeriy Vladimirovich Breder

First Author: Arndt Vogel

First Author: Richard S. Finn